

**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2024**

(Rs. in Lakhs)

Particulars	Quarter ended			Year ended
	30-Jun-24	31-Mar-24	30-Jun-23	31-Mar-24
	Unaudited	Audited (Refer Note 3)	Unaudited	Audited
1 Revenue from Operations	16,542	12,699	14,778	58,205
2 Other Income	237	165	181	721
<b>3 Total Income (1+2)</b>	<b>16,779</b>	<b>12,864</b>	<b>14,959</b>	<b>58,926</b>
<b>4 Expenses</b>				
(a) Cost of Materials Consumed	3,237	2,803	3,047	12,065
(b) Purchases of Stock-in-Trade	2,489	1,492	1,666	6,118
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(225)	(151)	305	270
(d) Employee Benefits Expense	3,274	3,208	3,279	13,215
(e) Finance Costs	15	14	7	45
(f) Depreciation and Amortisation Expense	529	449	421	1,707
(g) Other Expenses	3,860	3,275	3,257	13,722
<b>Total Expenses</b>	<b>13,179</b>	<b>11,090</b>	<b>11,982</b>	<b>47,142</b>
<b>5 Profit before tax (3-4)</b>	<b>3,600</b>	<b>1,774</b>	<b>2,977</b>	<b>11,784</b>
<b>6 Income tax expenses</b>				
a. Current Tax	951	545	792	3,254
b. Deferred Tax	(27)	(95)	(25)	(236)
<b>Total tax expenses</b>	<b>924</b>	<b>450</b>	<b>767</b>	<b>3,018</b>
<b>7 Profit for the period (5-6)</b>	<b>2,676</b>	<b>1,324</b>	<b>2,210</b>	<b>8,766</b>
<b>8 Other Comprehensive Income</b>				
(i) Items that will not be reclassified to Profit or Loss	2	(82)	2	(75)
(ii) Income tax relating to items that will not be reclassified to Profit or Loss	(1)	22	(1)	19
<b>Other Comprehensive Income Net of Tax</b>	<b>1</b>	<b>(60)</b>	<b>1</b>	<b>(56)</b>
<b>9 Total Comprehensive Income for the period (7+8)</b>	<b>2,677</b>	<b>1,264</b>	<b>2,211</b>	<b>8,710</b>
10 Paid-up Equity Share Capital (Face Value Rs. 8/- each)	1,323	1,323	1,323	1,323
11 Other Equity				36,162
12 Earnings per Share (of Rs. 8/- each) (not annualised for the quarter):				
(a) Basic (in Rs.)	16.18	8.01	13.36	53.01
(b) Diluted (in Rs.)	16.18	8.01	13.36	53.01

**Notes:**

- The above unaudited financial results have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at their respective meetings held on July 19, 2024.
- The Company operates in only one reportable business segment i.e. Pharmaceuticals.
- Figures of the quarter ended March 31, 2024 are the balancing figures between audited figures in respect of the full financial year and unaudited published year to date figure up to 31 December, 2023, which were subject to limited review.

For RPG Life Sciences Limited

Yugal Sikri  
DIN: 07576560  
Managing Director  
Mumbai, July 19 2024